A5024184100- Bladder and Urothelial Cancer Treatments
- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
- Photodynamic Therapy Research Studies
- Epigenetics and DNA Methylation
- Urinary and Genital Oncology Studies
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Urological Disorders and Treatments
- Lipid Membrane Structure and Behavior
- Renal and related cancers
- Electrochemical Analysis and Applications
- Urinary Bladder and Prostate Research
- Analytical Chemistry and Sensors
- Adrenal and Paraganglionic Tumors
- Pharmaceutical industry and healthcare
- Immune cells in cancer
- Advanced biosensing and bioanalysis techniques
- Renal cell carcinoma treatment
- Infectious Disease Case Reports and Treatments
- Urologic and reproductive health conditions
- Transplantation: Methods and Outcomes
- Pneumothorax, Barotrauma, Emphysema
- Pediatric Urology and Nephrology Studies
- Pneumocystis jirovecii pneumonia detection and treatment
Astellas Pharma (United States)
2024
National Institutes of Health
2014-2018
National Cancer Institute
2014-2018
University of Iowa
2017-2018
Center for Cancer Research
2017
Iowa City Public Library
2017
Cleveland Clinic
2014
Loyola University Chicago
2012
University of Missouri
2006
Saint Louis University
2001-2004
4503 Background: Enfortumab vedotin (EV) is approved in combination with pembrolizumab and as a monotherapy for locally advanced or metastatic urothelial cancer (la/mUC). EV, alone pembrolizumab, has demonstrated an OS benefit generally manageable safety profile patients (pts) previously treated untreated la/mUC. Dose modifications, including reductions interruptions, are recommended to manage EV-related AEs. This analysis evaluates the association between EV plasma exposure, which impacted...
The use of light as a means therapy for bladder cancer has long history but been hampered by lack tumor specificity and therefore, damage to the normal mucosa. Here, we describe targeted form phototherapy called photoimmunotherapy (PIT), which targets EGFR-expressing cancer. Anti-EGFR antibody panitumumab was labeled with photoabsorber (PA), IRDye 700Dx (IR700), create panitumumab-IR700 antibody-PA conjugate that is activated near-infrared radiation (NIR). Bladder tissue microarray (TMA)...
Purpose: To evaluate lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox®) in combination with loco-regional mild hyperthermia (HT) for targeted drug delivery to the bladder wall and potential treatment of cancer.Material methods: Porcine vivo studies were performed following groups: (i) intravenous (IV) LTLD (LTLD + HT); (ii) IV (DOX) (IV DOX HT) (iii) without – HT). Drug formulations delivered via 30 min infusion coinciding 1-h irrigation (45 °C water HT groups, 37 non-HT group),...
4564 Background: For patients (pts) with MIBC who are cisplatin-ineligible and undergoing radical cystectomy pelvic lymph node dissection (RC+PLND), no neoadjuvant treatment options have been shown to improve survival. Enfortumab vedotin (EV) is an antibody-drug conjugate directed Nectin-4, which highly expressed in urothelial cancer. EV, alone combination w/ pembrolizumab, has OS vs chemotherapy pts previously treated untreated locally advanced or metastatic cancer, respectively (Powles...
The Open Payments Program was enacted to increase transparency of financial relationships between physicians and the medical device pharmaceutical industry. We examined nonresearch related urologists industry in United States using latest data.We performed a descriptive analysis data released by Centers for Medicare Medicaid Services 2014. Total payment amounts associated with various urological drug categories were calculated. then correlations payments prescribing at national level Part D...
TPS4590 Background: High grade non-muscle invasive bladder cancer (NMIBC) has a 70% recurrence rate and of 15-30% progression. The standard care is an induction course bacillus Calmette-Guerin (BCG). A second can be used in patients who fail the initial course, however only 35% will experience 12 month disease free survival. For those failing radical cystectomy gold treatment, although morbidity high. Therefore there unmet need for localized treatment BCG. Recently, pox viral vector-based...
You have accessJournal of UrologyBladder Cancer: Non-invasive I1 Apr 2017MP15-10 IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM RANDOMIZED PHASE 2 CLINICAL TRIAL Thomas Sanford, Renee Donahue, Caroline Jochems, Rebecca Dolan, Sonia Bellfield, Megan Anderson, Eric Singer, Robert Weiss, Sammy Elsamra, Jang, Sam Brancato, Daniel Su, Yvonne Wall, James Gulley, Jeffrey Schlom, and Piyush Agarwal SanfordThomas Sanford , DonahueRenee Donahue JochemsCaroline...
BCG sepsis is rarely seen with modern intravesical therapy and therefore its presentation may not be apparent to recently trained urologists. We describe occurring in a patient treated combined intraurethral which resulted lung consolidation acid-fast bacilli requiring cessation of initiation systemic antibiotic therapy.
You have accessJournal of UrologyBladder Cancer: Non-invasive II (MP16)1 Sep 2021MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE STUDY TO DETERMINE THE EFFICACY BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG ALONE ADULTS HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER Ragheed Saoud, Siobhan Telfer, Mahir Maruf, Eric Singer, Robert Weiss, Thomas Jang, Sammy Elsamra, Maria Marino, Vladimir Valera, Beatriz Walter Rodriguez, Reema Railkar,...
Kinetic analysis of RNA enzymes, or ribozymes, typically involves the tedious process collecting and quenching reaction time points then fractionating by polyacrylamide gel electrophoresis (PAGE). As a way to automate simplify this process, continuous ribozyme is demonstrated here using completely automated capillary sample introduction onto microfabricated device with laser-induced fluorescence detection. The method injection extremely reproducible thereby standardizing data analysis. A...
A 46-year old man with X-linked chronic granulomatous disease (CGD) being followed at the National Institute of Health uncontrolled CGD colitis who developed colovesical fistula, and end-stage renal (ESRD). Despite aggressive medical management symptoms immunomodulators antibiotic prophylaxis, fistula led to pyelonephritis, recurrent urinary tract infections, persistent air in collecting system bladder, post-renal obstruction resulting failure. Patient is now hemodialysis dependent required...
In the past decade, electrochemists have begun modifying electrode surfaces with polymer composites. Each of those composites had advantages over standard modified electrode. Usually, major advantage is increased sensitivity. However, years chromatographic research proven that tailoring surface glass beads can increase selectivity a system. The same principle should be applicable to film This based upon making bead/ion exchange unique interfaces alter redox species on basis physical and...
You have accessJournal of UrologyGeneral & Epidemiological Trends Socioeconomics: Practice Patterns, Cost Effectiveness1 Apr 2011320 BOSNIAK II/IIF COMPLEX RENAL CYSTS: COST IMPLICATIONS OF SURVEILLANCE IMAGING Chandy Ellimoottil, Sam Brancato, Michael Ross, David Kollhoff, Philip Shalhoub, Joseph Allen, Sujeet Acharya, and Thomas Turk EllimoottilChandy Ellimoottil Maywood, IL More articles by this author , BrancatoSam Brancato RossMichael Ross KollhoffDavid Kollhoff ShalhoubPhilip Shalhoub...
You have accessJournal of UrologyBladder Cancer: Basic Research III1 Apr 2014MP34-14 TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR USING PHOTOIMMUNOTHERAPY IN THE TREATMENT OF BLADDER CANCER Sam Brancato, and Piyush Agarwal BrancatoSam Brancato More articles by this author , AgarwalPiyush View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1027AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND...
You have accessJournal of UrologyBladder Cancer: Basic Research III1 Apr 2014MP34-15 ASSESSING THE THERAPEUTIC BENEFIT OF MDV3100 IN TARGETING ANDROGEN RECEPTOR BLADDER CANCER Sam Brancato, and Piyush Agarwal BrancatoSam Brancato More articles by this author , AgarwalPiyush View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1028AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The...